Literature DB >> 20506395

Multivariate data analysis on historical IPV production data for better process understanding and future improvements.

Yvonne E Thomassen1, Eric N M van Sprang, Leo A van der Pol, Wilfried A M Bakker.   

Abstract

Historical manufacturing data can potentially harbor a wealth of information for process optimization and enhancement of efficiency and robustness. To extract useful data multivariate data analysis (MVDA) using projection methods is often applied. In this contribution, the results obtained from applying MVDA on data from inactivated polio vaccine (IPV) production runs are described. Data from over 50 batches at two different production scales (700-L and 1,500-L) were available. The explorative analysis performed on single unit operations indicated consistent manufacturing. Known outliers (e.g., rejected batches) were identified using principal component analysis (PCA). The source of operational variation was pinpointed to variation of input such as media. Other relevant process parameters were in control and, using this manufacturing data, could not be correlated to product quality attributes. The gained knowledge of the IPV production process, not only from the MVDA, but also from digitalizing the available historical data, has proven to be useful for troubleshooting, understanding limitations of available data and seeing the opportunity for improvements. 2010 Wiley Periodicals, Inc.

Mesh:

Substances:

Year:  2010        PMID: 20506395     DOI: 10.1002/bit.22788

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  6 in total

Review 1.  Monitoring Quality of Biotherapeutic Products Using Multivariate Data Analysis.

Authors:  Anurag S Rathore; Mili Pathak; Renu Jain; Gaurav Pratap Singh Jadaun
Journal:  AAPS J       Date:  2016-04-04       Impact factor: 4.009

2.  Hematopoietic cancer cell lines can support replication of Sabin poliovirus type 1.

Authors:  Dinja Oosterhoff; Gerard van de Weerd; Gerco van Eikenhorst; Tanja D de Gruijl; Leo A van der Pol; Wilfried A M Bakker
Journal:  Biomed Res Int       Date:  2015-02-28       Impact factor: 3.411

3.  Incompatibility of lyophilized inactivated polio vaccine with liquid pentavalent whole-cell-pertussis-containing vaccine.

Authors:  Heleen Kraan; Rimko Ten Have; Larissa van der Maas; Gideon Kersten; Jean-Pierre Amorij
Journal:  Vaccine       Date:  2016-07-26       Impact factor: 3.641

Review 4.  Factors Affecting Microalgae Production for Biofuels and the Potentials of Chemometric Methods in Assessing and Optimizing Productivity.

Authors:  Mutah Musa; Godwin A Ayoko; Andrew Ward; Christine Rösch; Richard J Brown; Thomas J Rainey
Journal:  Cells       Date:  2019-08-07       Impact factor: 6.600

5.  Immunogenicity and Safety of Inactivated Sabin-Strain Polio Vaccine "PoliovacSin": Clinical Trials Phase I and II.

Authors:  Anastasia Piniaeva; Georgy Ignatyev; Liubov Kozlovskaya; Yury Ivin; Anastasia Kovpak; Alexander Ivanov; Anna Shishova; Liliia Antonova; Yusuf Khapchaev; Irina Feldblium; Olga Ivanova; Aleksandra Siniugina; Aydar Ishmukhametov
Journal:  Vaccines (Basel)       Date:  2021-05-29

6.  Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals.

Authors:  Yvonne E Thomassen; Aart G van 't Oever; Monique G C T van Oijen; René H Wijffels; Leo A van der Pol; Wilfried A M Bakker
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.